NO314566B1 - Doseringsform med regulert frigivelse belagt med vandige dispersjoner av etylcellulose, samt fremgangsmåte og anvendelse - Google Patents

Doseringsform med regulert frigivelse belagt med vandige dispersjoner av etylcellulose, samt fremgangsmåte og anvendelse Download PDF

Info

Publication number: NO314566B1
Authority: NO; Norway
Prior art keywords: active agent; specified; release; coated; dosage form
Prior art date: 1993-06-23

Application number

NO19942382A

Other languages

English (en)

Norwegian (no)

Other versions

NO942382D0 (de

NO942382L (no

Inventor

Benjamin Oshlack

Mark Chasin

Frank Pedi

Original Assignee

Euro Celtique Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-06-23

Filing date

1994-06-22

Publication date

2003-04-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22165285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO314566(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-06-22 Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa

1994-06-22 Publication of NO942382D0 publication Critical patent/NO942382D0/no

1994-12-27 Publication of NO942382L publication Critical patent/NO942382L/no

2003-04-14 Publication of NO314566B1 publication Critical patent/NO314566B1/no

Links

238000013270 controlled release Methods 0.000 title claims abstract description 104
239000006185 dispersion Substances 0.000 title claims abstract description 63
239000002552 dosage form Substances 0.000 title claims abstract description 44
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 title claims description 121
239000001856 Ethyl cellulose Substances 0.000 title claims description 63
235000019325 ethyl cellulose Nutrition 0.000 title claims description 63
229920001249 ethyl cellulose Polymers 0.000 title claims description 63
238000000034 method Methods 0.000 title claims description 43
238000000576 coating method Methods 0.000 claims abstract description 114
239000011248 coating agent Substances 0.000 claims abstract description 99
239000000758 substrate Substances 0.000 claims abstract description 93
BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims abstract description 8
230000001225 therapeutic effect Effects 0.000 claims abstract description 7
229960002085 oxycodone Drugs 0.000 claims abstract description 5
238000004090 dissolution Methods 0.000 claims description 120
239000011324 bead Substances 0.000 claims description 118
239000013543 active substance Substances 0.000 claims description 105
239000000203 mixture Substances 0.000 claims description 88
238000003860 storage Methods 0.000 claims description 59
238000009472 formulation Methods 0.000 claims description 56
WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 46
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 44
229960001410 hydromorphone Drugs 0.000 claims description 43
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 43
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 42
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 38
238000000338 in vitro Methods 0.000 claims description 38
-1 antihypotensives Substances 0.000 claims description 37
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 37
239000004014 plasticizer Substances 0.000 claims description 35
239000003795 chemical substances by application Substances 0.000 claims description 34
239000000243 solution Substances 0.000 claims description 34
239000002775 capsule Substances 0.000 claims description 30
229920000642 polymer Polymers 0.000 claims description 30
230000004584 weight gain Effects 0.000 claims description 28
235000019786 weight gain Nutrition 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 24
239000012530 fluid Substances 0.000 claims description 24
229960000278 theophylline Drugs 0.000 claims description 22
230000036765 blood level Effects 0.000 claims description 21
238000004519 manufacturing process Methods 0.000 claims description 19
239000011148 porous material Substances 0.000 claims description 18
230000002496 gastric effect Effects 0.000 claims description 15
239000007787 solid Substances 0.000 claims description 15
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 14
230000009477 glass transition Effects 0.000 claims description 13
239000003607 modifier Substances 0.000 claims description 11
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
239000012062 aqueous buffer Substances 0.000 claims description 9
230000001105 regulatory effect Effects 0.000 claims description 9
229940124597 therapeutic agent Drugs 0.000 claims description 9
OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 8
229940075614 colloidal silicon dioxide Drugs 0.000 claims description 8
229960005181 morphine Drugs 0.000 claims description 7
238000009506 drug dissolution testing Methods 0.000 claims description 6
239000003172 expectorant agent Substances 0.000 claims description 6
229920001477 hydrophilic polymer Polymers 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
238000011068 loading method Methods 0.000 claims description 5
239000002245 particle Substances 0.000 claims description 5
239000000021 stimulant Substances 0.000 claims description 5
239000000730 antalgic agent Substances 0.000 claims description 4
239000003434 antitussive agent Substances 0.000 claims description 4
229940124584 antitussives Drugs 0.000 claims description 4
229960004126 codeine Drugs 0.000 claims description 4
OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
229910052751 metal Inorganic materials 0.000 claims description 4
239000002184 metal Substances 0.000 claims description 4
239000006186 oral dosage form Substances 0.000 claims description 4
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 4
IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims description 3
230000000954 anitussive effect Effects 0.000 claims description 3
239000000924 antiasthmatic agent Substances 0.000 claims description 3
239000001961 anticonvulsive agent Substances 0.000 claims description 3
229940125714 antidiarrheal agent Drugs 0.000 claims description 3
239000003793 antidiarrheal agent Substances 0.000 claims description 3
239000002111 antiemetic agent Substances 0.000 claims description 3
229940125683 antiemetic agent Drugs 0.000 claims description 3
239000000739 antihistaminic agent Substances 0.000 claims description 3
229940125715 antihistaminic agent Drugs 0.000 claims description 3
239000002220 antihypertensive agent Substances 0.000 claims description 3
229940030600 antihypertensive agent Drugs 0.000 claims description 3
229940124572 antihypotensive agent Drugs 0.000 claims description 3
239000003443 antiviral agent Substances 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 3
229940124630 bronchodilator Drugs 0.000 claims description 3
239000000168 bronchodilator agent Substances 0.000 claims description 3
RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 claims description 3
229960001736 buprenorphine Drugs 0.000 claims description 3
239000000850 decongestant Substances 0.000 claims description 3
229940124581 decongestants Drugs 0.000 claims description 3
229960000920 dihydrocodeine Drugs 0.000 claims description 3
RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims description 3
XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 3
239000002934 diuretic Substances 0.000 claims description 3
230000003419 expectorant effect Effects 0.000 claims description 3
229940066493 expectorants Drugs 0.000 claims description 3
239000003326 hypnotic agent Substances 0.000 claims description 3
239000008141 laxative Substances 0.000 claims description 3
229940125722 laxative agent Drugs 0.000 claims description 3
229940066491 mucolytics Drugs 0.000 claims description 3
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 3
239000004089 psychotropic agent Substances 0.000 claims description 3
239000000932 sedative agent Substances 0.000 claims description 3
229940125723 sedative agent Drugs 0.000 claims description 3
239000007909 solid dosage form Substances 0.000 claims description 3
150000003431 steroids Chemical class 0.000 claims description 3
229940124549 vasodilator Drugs 0.000 claims description 3
239000003071 vasodilator agent Substances 0.000 claims description 3
239000011782 vitamin Substances 0.000 claims description 3
229940088594 vitamin Drugs 0.000 claims description 3
235000013343 vitamin Nutrition 0.000 claims description 3
229930003231 vitamin Natural products 0.000 claims description 3
230000001088 anti-asthma Effects 0.000 claims description 2
239000005555 hypertensive agent Substances 0.000 claims description 2
230000000147 hypnotic effect Effects 0.000 claims description 2
USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims 2
GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 2
JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 2
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims 2
239000003242 anti bacterial agent Substances 0.000 claims 2
229940088710 antibiotic agent Drugs 0.000 claims 2
229960002069 diamorphine Drugs 0.000 claims 2
229940030606 diuretics Drugs 0.000 claims 2
239000004083 gastrointestinal agent Substances 0.000 claims 2
229940125695 gastrointestinal agent Drugs 0.000 claims 2
239000005556 hormone Substances 0.000 claims 2
229940088597 hormone Drugs 0.000 claims 2
229960003406 levorphanol Drugs 0.000 claims 2
229960001797 methadone Drugs 0.000 claims 2
239000000014 opioid analgesic Substances 0.000 claims 2
229960000482 pethidine Drugs 0.000 claims 2
230000001142 anti-diarrhea Effects 0.000 claims 1
230000002959 anti-hypotensive effect Effects 0.000 claims 1
229940121357 antivirals Drugs 0.000 claims 1
230000000510 mucolytic effect Effects 0.000 claims 1
229940001470 psychoactive drug Drugs 0.000 claims 1
230000000506 psychotropic effect Effects 0.000 claims 1
229920001600 hydrophobic polymer Polymers 0.000 abstract description 6
239000003826 tablet Substances 0.000 description 44
239000000047 product Substances 0.000 description 39
238000001723 curing Methods 0.000 description 31
230000000052 comparative effect Effects 0.000 description 24
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 20
239000011162 core material Substances 0.000 description 20
208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 17
229940079593 drug Drugs 0.000 description 15
GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 15
229960004715 morphine sulfate Drugs 0.000 description 14
239000000725 suspension Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 13
DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 12
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
239000012729 immediate-release (IR) formulation Substances 0.000 description 12
239000008188 pellet Substances 0.000 description 12
239000001069 triethyl citrate Substances 0.000 description 12
VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 12
235000013769 triethyl citrate Nutrition 0.000 description 12
235000010980 cellulose Nutrition 0.000 description 11
229920002678 cellulose Polymers 0.000 description 11
230000008859 change Effects 0.000 description 11
239000001913 cellulose Substances 0.000 description 10
239000000975 dye Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 8
229920002301 cellulose acetate Polymers 0.000 description 8
239000003205 fragrance Substances 0.000 description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
230000009467 reduction Effects 0.000 description 7
238000001878 scanning electron micrograph Methods 0.000 description 7
239000000126 substance Substances 0.000 description 7
239000004202 carbamide Substances 0.000 description 6
239000003337 fertilizer Substances 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
230000002209 hydrophobic effect Effects 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
230000000979 retarding effect Effects 0.000 description 6
ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 5
239000000645 desinfectant Substances 0.000 description 5
238000010348 incorporation Methods 0.000 description 5
238000002156 mixing Methods 0.000 description 5
239000003960 organic solvent Substances 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000008213 purified water Substances 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
238000005507 spraying Methods 0.000 description 5
239000004094 surface-active agent Substances 0.000 description 5
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
238000004581 coalescence Methods 0.000 description 4
238000007922 dissolution test Methods 0.000 description 4
238000001035 drying Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
230000007774 longterm Effects 0.000 description 4
239000012528 membrane Substances 0.000 description 4
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
230000000704 physical effect Effects 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
150000004804 polysaccharides Chemical class 0.000 description 4
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
230000008569 process Effects 0.000 description 4
239000004408 titanium dioxide Substances 0.000 description 4
235000008733 Citrus aurantifolia Nutrition 0.000 description 3
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
229920003091 Methocel™ Polymers 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
235000011941 Tilia x europaea Nutrition 0.000 description 3
239000012754 barrier agent Substances 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000012459 cleaning agent Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000002781 deodorant agent Substances 0.000 description 3
229940099212 dilaudid Drugs 0.000 description 3
238000005538 encapsulation Methods 0.000 description 3
230000007613 environmental effect Effects 0.000 description 3
230000003628 erosive effect Effects 0.000 description 3
239000000417 fungicide Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
239000004009 herbicide Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000000077 insect repellent Substances 0.000 description 3
239000004571 lime Substances 0.000 description 3
239000012229 microporous material Substances 0.000 description 3
239000011049 pearl Substances 0.000 description 3
239000002304 perfume Substances 0.000 description 3
239000000575 pesticide Substances 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000008635 plant growth Effects 0.000 description 3
230000036470 plasma concentration Effects 0.000 description 3
229920000728 polyester Polymers 0.000 description 3
229920002635 polyurethane Polymers 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000005871 repellent Substances 0.000 description 3
230000002940 repellent Effects 0.000 description 3
239000008107 starch Substances 0.000 description 3
NDDLLTAIKYHPOD-ISLYRVAYSA-N (2e)-6-chloro-2-(6-chloro-4-methyl-3-oxo-1-benzothiophen-2-ylidene)-4-methyl-1-benzothiophen-3-one Chemical compound S/1C2=CC(Cl)=CC(C)=C2C(=O)C\1=C1/SC(C=C(Cl)C=C2C)=C2C1=O NDDLLTAIKYHPOD-ISLYRVAYSA-N 0.000 description 2
YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 2
229920000178 Acrylic resin Polymers 0.000 description 2
239000004925 Acrylic resin Substances 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
229920000623 Cellulose acetate phthalate Polymers 0.000 description 2
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
239000005715 Fructose Substances 0.000 description 2
229930091371 Fructose Natural products 0.000 description 2
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
239000004098 Tetracycline Substances 0.000 description 2
229920002494 Zein Polymers 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
239000003708 ampul Substances 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
239000002585 base Substances 0.000 description 2
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
235000010418 carrageenan Nutrition 0.000 description 2
229920001525 carrageenan Polymers 0.000 description 2
239000000679 carrageenan Substances 0.000 description 2
229940113118 carrageenan Drugs 0.000 description 2
229940081734 cellulose acetate phthalate Drugs 0.000 description 2
229920003086 cellulose ether Polymers 0.000 description 2
229960003260 chlorhexidine Drugs 0.000 description 2
239000000460 chlorine Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
229940075484 d&c red no. 30 Drugs 0.000 description 2
238000010586 diagram Methods 0.000 description 2
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
229940000406 drug candidate Drugs 0.000 description 2
239000013583 drug formulation Substances 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000013020 final formulation Substances 0.000 description 2
230000002070 germicidal effect Effects 0.000 description 2
238000011194 good manufacturing practice Methods 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000003456 ion exchange resin Substances 0.000 description 2
229920003303 ion-exchange polymer Polymers 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229960001047 methyl salicylate Drugs 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
235000019426 modified starch Nutrition 0.000 description 2
239000002547 new drug Substances 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
230000035699 permeability Effects 0.000 description 2
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
229960000395 phenylpropanolamine Drugs 0.000 description 2
239000000049 pigment Substances 0.000 description 2
229920001467 poly(styrenesulfonates) Polymers 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
229920000915 polyvinyl chloride Polymers 0.000 description 2
239000004800 polyvinyl chloride Substances 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
239000004323 potassium nitrate Substances 0.000 description 2
235000010333 potassium nitrate Nutrition 0.000 description 2
OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
229910052939 potassium sulfate Inorganic materials 0.000 description 2
235000011151 potassium sulphates Nutrition 0.000 description 2
229960004618 prednisone Drugs 0.000 description 2
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000011253 protective coating Substances 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000035882 stress Effects 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
229950009390 symclosene Drugs 0.000 description 2
229960002180 tetracycline Drugs 0.000 description 2
229930101283 tetracycline Natural products 0.000 description 2
235000019364 tetracycline Nutrition 0.000 description 2
150000003522 tetracyclines Chemical class 0.000 description 2
MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
235000010215 titanium dioxide Nutrition 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
239000001993 wax Substances 0.000 description 2
239000005019 zein Substances 0.000 description 2
229940093612 zein Drugs 0.000 description 2
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
WBKYGCZSBGEBFP-UHFFFAOYSA-N 5-butoxy-3-butoxycarbonyl-3-hydroxy-5-oxopentanoic acid Chemical compound CCCCOC(=O)CC(O)(CC(O)=O)C(=O)OCCCC WBKYGCZSBGEBFP-UHFFFAOYSA-N 0.000 description 1
RKETZVBQTUSNLM-UHFFFAOYSA-N 6-(3-bromophenyl)-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole Chemical compound BrC1=CC=CC(C2N=C3SCCN3C2)=C1 RKETZVBQTUSNLM-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
240000004507 Abelmoschus esculentus Species 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
229920000945 Amylopectin Polymers 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
229920002498 Beta-glucan Polymers 0.000 description 1
229930185605 Bisphenol Natural products 0.000 description 1
ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010007269 Carcinogenicity Diseases 0.000 description 1
229920001747 Cellulose diacetate Polymers 0.000 description 1
229920002284 Cellulose triacetate Polymers 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
244000303965 Cyamopsis psoralioides Species 0.000 description 1
235000017788 Cydonia oblonga Nutrition 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
229920003136 Eudragit® L polymer Polymers 0.000 description 1
239000005980 Gibberellic acid Substances 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
244000178870 Lavandula angustifolia Species 0.000 description 1
235000010663 Lavandula angustifolia Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000006240 Linum usitatissimum Species 0.000 description 1
235000004431 Linum usitatissimum Nutrition 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229920002821 Modacrylic Polymers 0.000 description 1
239000004368 Modified starch Substances 0.000 description 1
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
239000006057 Non-nutritive feed additive Substances 0.000 description 1
229920002302 Nylon 6,6 Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
208000005888 Periodontal Pocket Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
244000134552 Plantago ovata Species 0.000 description 1
235000003421 Plantago ovata Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001100 Polydextrose Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
229920000153 Povidone-iodine Polymers 0.000 description 1
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
239000009223 Psyllium Substances 0.000 description 1
229920002305 Schizophyllan Polymers 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
241001634922 Tausonia pullulans Species 0.000 description 1
241000736873 Tetraclinis articulata Species 0.000 description 1
239000005844 Thymol Substances 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
SPEUIVXLLWOEMJ-UHFFFAOYSA-N acetaldehyde dimethyl acetal Natural products COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
RFUZHZOLHOAGIX-UHFFFAOYSA-N acetic acid;2-chloroacetic acid Chemical compound CC(O)=O.OC(=O)CCl RFUZHZOLHOAGIX-UHFFFAOYSA-N 0.000 description 1
YMNMXQILQOXZPB-UHFFFAOYSA-N acetic acid;4-methylbenzenesulfonic acid Chemical compound CC(O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 YMNMXQILQOXZPB-UHFFFAOYSA-N 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
GJAYYEWRFJQMQK-UHFFFAOYSA-N acetic acid;ethyl carbamate Chemical compound CC(O)=O.CCOC(N)=O GJAYYEWRFJQMQK-UHFFFAOYSA-N 0.000 description 1
MFOPEVCFSVUADB-UHFFFAOYSA-N acetic acid;methyl carbamate Chemical compound CC(O)=O.COC(N)=O MFOPEVCFSVUADB-UHFFFAOYSA-N 0.000 description 1
ASRPLWIDQZYBQK-UHFFFAOYSA-N acetic acid;pentanoic acid Chemical compound CC(O)=O.CCCCC(O)=O ASRPLWIDQZYBQK-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
230000032683 aging Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000012670 alkaline solution Substances 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
229940069428 antacid Drugs 0.000 description 1
239000003159 antacid agent Substances 0.000 description 1
230000000170 anti-cariogenic effect Effects 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000003556 anti-epileptic effect Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000002882 anti-plaque Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229960003965 antiepileptics Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
239000002830 appetite depressant Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960005274 benzocaine Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229960002537 betamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
229910052796 boron Inorganic materials 0.000 description 1
239000008376 breath freshener Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
125000005587 carbonate group Chemical group 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
231100000260 carcinogenicity Toxicity 0.000 description 1
230000007670 carcinogenicity Effects 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
229920006217 cellulose acetate butyrate Polymers 0.000 description 1
229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
229960001927 cetylpyridinium chloride Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
229930002875 chlorophyll Natural products 0.000 description 1
235000019804 chlorophyll Nutrition 0.000 description 1
ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
229940046978 chlorpheniramine maleate Drugs 0.000 description 1
229960005233 cineole Drugs 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000008199 coating composition Substances 0.000 description 1
229960004415 codeine phosphate Drugs 0.000 description 1
239000008119 colloidal silica Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
229960001378 dequalinium chloride Drugs 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960005372 dexchlorpheniramine maleate Drugs 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
SNDDIRAXSDUVKW-URVXVIKDSA-N dextromethorphan hcl Chemical compound Cl.C([C@@H]12)CCC[C@]11CCN(C)[C@H]2CC2=CC=C(OC)C=C21 SNDDIRAXSDUVKW-URVXVIKDSA-N 0.000 description 1
229960005257 dextromethorphan hydrochloride Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940099371 diacetylated monoglycerides Drugs 0.000 description 1
MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
229940116349 dibasic ammonium phosphate Drugs 0.000 description 1
229940111685 dibasic potassium phosphate Drugs 0.000 description 1
IKJFYINYNJYDTA-UHFFFAOYSA-N dibenzothiophene sulfone Chemical compound C1=CC=C2S(=O)(=O)C3=CC=CC=C3C2=C1 IKJFYINYNJYDTA-UHFFFAOYSA-N 0.000 description 1
CEJLBZWIKQJOAT-UHFFFAOYSA-N dichloroisocyanuric acid Chemical compound ClN1C(=O)NC(=O)N(Cl)C1=O CEJLBZWIKQJOAT-UHFFFAOYSA-N 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
229960004166 diltiazem Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
229960004993 dimenhydrinate Drugs 0.000 description 1
PSHRANCNVXNITH-UHFFFAOYSA-N dimethylamino acetate Chemical compound CN(C)OC(C)=O PSHRANCNVXNITH-UHFFFAOYSA-N 0.000 description 1
150000002009 diols Chemical class 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000004815 dispersion polymer Substances 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
229960003199 etacrynic acid Drugs 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000006355 external stress Effects 0.000 description 1
235000020937 fasting conditions Nutrition 0.000 description 1
239000003925 fat Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
235000004426 flaxseed Nutrition 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000010437 gem Substances 0.000 description 1
IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
230000002363 herbicidal effect Effects 0.000 description 1
229960003258 hexylresorcinol Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
239000012943 hotmelt Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
229960004716 idoxuridine Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
229910017053 inorganic salt Inorganic materials 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
239000001034 iron oxide pigment Substances 0.000 description 1
230000001788 irregular Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
239000004816 latex Substances 0.000 description 1
229920000126 latex Polymers 0.000 description 1
239000001102 lavandula vera Substances 0.000 description 1
235000018219 lavender Nutrition 0.000 description 1
XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
229910052808 lithium carbonate Inorganic materials 0.000 description 1
LWXVCCOAQYNXNX-UHFFFAOYSA-N lithium hypochlorite Chemical compound [Li+].Cl[O-] LWXVCCOAQYNXNX-UHFFFAOYSA-N 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
229960005015 local anesthetics Drugs 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
229960004815 meprobamate Drugs 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
229960004503 metoclopramide Drugs 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000011785 micronutrient Substances 0.000 description 1
235000013369 micronutrients Nutrition 0.000 description 1
239000008185 minitablet Substances 0.000 description 1
239000011733 molybdenum Substances 0.000 description 1
229910052750 molybdenum Inorganic materials 0.000 description 1
239000006012 monoammonium phosphate Substances 0.000 description 1
235000019837 monoammonium phosphate Nutrition 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
229960001454 nitrazepam Drugs 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
229960001774 octenidine Drugs 0.000 description 1
SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229940113162 oleylamide Drugs 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000008023 pharmaceutical filler Substances 0.000 description 1
239000008019 pharmaceutical lubricant Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000001863 plant nutrition Effects 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000005498 polishing Methods 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002492 poly(sulfone) Polymers 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001515 polyalkylene glycol Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
235000013856 polydextrose Nutrition 0.000 description 1
239000001259 polydextrose Substances 0.000 description 1
229940035035 polydextrose Drugs 0.000 description 1
229920000867 polyelectrolyte Polymers 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
ODGAOXROABLFNM-UHFFFAOYSA-N polynoxylin Chemical class O=C.NC(N)=O ODGAOXROABLFNM-UHFFFAOYSA-N 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920000131 polyvinylidene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000011118 potassium hydroxide Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
239000001120 potassium sulphate Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229960001621 povidone-iodine Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
238000003672 processing method Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
229940070687 psyllium Drugs 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000003340 retarding agent Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
239000005060 rubber Substances 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
229960002646 scopolamine Drugs 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
239000000344 soap Substances 0.000 description 1
235000015424 sodium Nutrition 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
MSFGZHUJTJBYFA-UHFFFAOYSA-M sodium dichloroisocyanurate Chemical compound [Na+].ClN1C(=O)[N-]C(=O)N(Cl)C1=O MSFGZHUJTJBYFA-UHFFFAOYSA-M 0.000 description 1
229960004711 sodium monofluorophosphate Drugs 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
229960002799 stannous fluoride Drugs 0.000 description 1
229920001909 styrene-acrylic polymer Polymers 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
229960000894 sulindac Drugs 0.000 description 1
MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009182 swimming Effects 0.000 description 1
XRCRWCVBMHENNE-UHFFFAOYSA-N sym-di-n-butyl citrate Natural products CCCCOC(=O)CC(O)(C(O)=O)CC(=O)OCCCC XRCRWCVBMHENNE-UHFFFAOYSA-N 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
229960000790 thymol Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
229960005294 triamcinolone Drugs 0.000 description 1
GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000002888 zwitterionic surfactant Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cosmetics (AREA)

NO19942382A 1993-06-23 1994-06-22 Doseringsform med regulert frigivelse belagt med vandige dispersjoner av etylcellulose, samt fremgangsmåte og anvendelse NO314566B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/081,618 US5472712A (en)	1991-12-24	1993-06-23	Controlled-release formulations coated with aqueous dispersions of ethylcellulose

Publications (3)

Publication Number	Publication Date
NO942382D0 NO942382D0 (de)	1994-06-22
NO942382L NO942382L (no)	1994-12-27
NO314566B1 true NO314566B1 (no)	2003-04-14

Family

ID=22165285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19942382A NO314566B1 (no)	1993-06-23	1994-06-22	Doseringsform med regulert frigivelse belagt med vandige dispersjoner av etylcellulose, samt fremgangsmåte og anvendelse

Country Status (14)

Country	Link
US (1)	US5472712A (de)
EP (9)	EP1504757A3 (de)
JP (3)	JP4505059B2 (de)
AT (3)	ATE221375T1 (de)
AU (2)	AU680491B2 (de)
CA (1)	CA2125904C (de)
DE (3)	DE69434515T2 (de)
DK (3)	DK1477162T3 (de)
ES (3)	ES2315599T3 (de)
FI (1)	FI121620B (de)
HK (1)	HK1048432A1 (de)
NO (1)	NO314566B1 (de)
PT (2)	PT1477162E (de)
SI (2)	SI1419766T1 (de)

Families Citing this family (220)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5580578A (en) *	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5968551A (en)	1991-12-24	1999-10-19	Purdue Pharma L.P.	Orally administrable opioid formulations having extended duration of effect
US5958459A (en) *	1991-12-24	1999-09-28	Purdue Pharma L.P.	Opioid formulations having extended controlled released
US5681585A (en) *	1991-12-24	1997-10-28	Euro-Celtique, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5478577A (en) *	1993-11-23	1995-12-26	Euroceltique, S.A.	Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US7070806B2 (en) *	1992-01-27	2006-07-04	Purdue Pharma Lp	Controlled release formulations coated with aqueous dispersions of acrylic polymers
NZ260408A (en)	1993-05-10	1996-05-28	Euro Celtique Sa	Controlled release preparation comprising tramadol
US7740881B1 (en)	1993-07-01	2010-06-22	Purdue Pharma Lp	Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) *	1993-07-01	1999-11-30	Euro Celtique Sa	Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) *	1993-07-27	1999-03-09	Euro-Celtique S.A.	Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5773025A (en) *	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
EP1442745A1 (de)	1993-10-07	2004-08-04	Euro-Celtique	Oral anzuwendende opioidhaltige Zusammensetzungen mit verlängerter Wirkung
US5891471A (en) *	1993-11-23	1999-04-06	Euro-Celtique, S.A.	Pharmaceutical multiparticulates
US5914131A (en) *	1994-07-07	1999-06-22	Alza Corporation	Hydromorphone therapy
US20020006438A1 (en) *	1998-09-25	2002-01-17	Benjamin Oshlack	Sustained release hydromorphone formulations exhibiting bimodal characteristics
US5965161A (en) *	1994-11-04	1999-10-12	Euro-Celtique, S.A.	Extruded multi-particulates
US5871776A (en) *	1995-01-31	1999-02-16	Mehta; Atul M.	Controlled-release nifedipine
WO1996041622A1 (en) *	1995-06-09	1996-12-27	R.P. Scherer Corporation	Soft gelatin capsules containing particulate material
GB9519363D0 (en)	1995-09-22	1995-11-22	Euro Celtique Sa	Pharmaceutical formulation
US5733578A (en) *	1995-11-15	1998-03-31	Edward Mendell Co., Inc.	Directly compressible high load acetaminophen formulations
US6245351B1 (en)	1996-03-07	2001-06-12	Takeda Chemical Industries, Ltd.	Controlled-release composition
US5939356A (en) *	1996-06-21	1999-08-17	Southwest Research Institute	Controlled release coated agricultural products
DE69732983T2 (de) *	1996-09-13	2006-02-16	Shionogi & Co., Ltd.	Zubereitung mit verlängerter freisetzung unter verwendung einer thermischen umwandlung sowie verfahren zu deren herstellung
US5807580A (en) *	1996-10-30	1998-09-15	Mcneil-Ppc, Inc.	Film coated tablet compositions having enhanced disintegration characteristics
US6180128B1 (en) *	1997-01-27	2001-01-30	C-Cure Corp.	Non-carcinogenic substitute for play sand
CA2270975C (en)	1997-07-02	2003-04-01	Euro-Celtique, S.A.	Stabilized sustained release tramadol formulations
RS49982B (sr) *	1997-09-17	2008-09-29	Euro-Celtique S.A.,	Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6426116B1 (en)	1997-10-15	2002-07-30	University Of South Florida	Supercritical fluid aided coating of particulate material
US6485748B1 (en) *	1997-12-12	2002-11-26	Andrx Pharmaceuticals, Inc.	Once daily pharmaceutical tablet having a unitary core
US20040029962A1 (en) *	1997-12-12	2004-02-12	Chih-Ming Chen	HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) *	1997-12-12	2006-06-29	Andrx Labs Llc	HMG-CoA reductase inhibitor extended release formulation
EP1041987B1 (de)	1997-12-22	2006-04-19	Euro-Celtique S.A.	Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
US6375957B1 (en)	1997-12-22	2002-04-23	Euro-Celtique, S.A.	Opioid agonist/opioid antagonist/acetaminophen combinations
US6245357B1 (en) *	1998-03-06	2001-06-12	Alza Corporation	Extended release dosage form
US8524277B2 (en) *	1998-03-06	2013-09-03	Alza Corporation	Extended release dosage form
US5976507A (en) *	1998-06-04	1999-11-02	Colgate Palmolive Company	Dentrifice composition containing encapsulated reactive ingredients
US6806294B2 (en)	1998-10-15	2004-10-19	Euro-Celtique S.A.	Opioid analgesic
DE19901686A1 (de) *	1999-01-18	2000-07-20	Gruenenthal Gmbh	Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
US6432448B1 (en) *	1999-02-08	2002-08-13	Fmc Corporation	Edible coating composition
US6723342B1 (en)	1999-02-08	2004-04-20	Fmc Corporation	Edible coating composition
US6555139B2 (en)	1999-06-28	2003-04-29	Wockhardt Europe Limited	Preparation of micron-size pharmaceutical particles by microfluidization
CN100391438C (zh) *	1999-09-14	2008-06-04	史密丝克莱恩比彻姆公司	制备水性包被小球粒的方法
AU764453B2 (en) *	1999-10-29	2003-08-21	Euro-Celtique S.A.	Controlled release hydrocodone formulations
US6500462B1 (en)	1999-10-29	2002-12-31	Fmc Corporation	Edible MCC/PGA coating composition
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
IL151058A0 (en)	2000-02-08	2003-04-10	Euro Celtique Sa	Controlled-release compositions containing opioid agonist and antagonist
EP2092936B1 (de)	2000-02-08	2013-03-20	Euro-Celtique S.A.	Missbrauchssichere orale Opioidagonisten-Formulierungen
GB0007419D0 (en) †	2000-03-27	2000-05-17	Smithkline Beecham Gmbh	Composition
SE0001151D0 (sv)	2000-03-31	2000-03-31	Amarin Dev Ab	Method for producing a controlled-release composition
US6635277B2 (en)	2000-04-12	2003-10-21	Wockhardt Limited	Composition for pulsatile delivery of diltiazem and process of manufacture
US6663686B1 (en)	2000-06-27	2003-12-16	Agrium, Inc.	Controlled release fertilizer and method for production thereof
MXPA03003895A (es)	2000-10-30	2003-07-28	Euro Celtique Sa	Formulaciones de hidrocodona de liberacion controlada.
US6932861B2 (en)	2000-11-28	2005-08-23	Fmc Corporation	Edible PGA coating composition
IL155959A0 (en)	2000-11-28	2003-12-23	Fmc Corp	Edible pga (propylene glycol alginate) coating composition
US6486248B2 (en)	2001-01-08	2002-11-26	Milliken & Company	Liquid colorant and method
US6878309B2 (en) *	2001-02-12	2005-04-12	Dober Chemical Corp.	Controlled release cooling additive composition
EP1385486A4 (de) *	2001-04-18	2006-05-17	Nostrum Pharmaceuticals Inc	Neuartiger überzug für eine pharmazeutische zusammensetzung mit verzögerter freisetzung
UA81224C2 (uk)	2001-05-02	2007-12-25	Euro Celtic S A	Дозована форма оксикодону та її застосування
US20110104214A1 (en) *	2004-04-15	2011-05-05	Purdue Pharma L.P.	Once-a-day oxycodone formulations
EP1387673B1 (de)	2001-05-11	2010-12-29	Endo Pharmaceuticals Inc.	Opioid enthaltende arzneiform gegen missbrauch
US20030070584A1 (en) *	2001-05-15	2003-04-17	Cynthia Gulian	Dip coating compositions containing cellulose ethers
US7052706B2 (en) *	2001-06-08	2006-05-30	Nostrum Pharmaceuticals, Inc.	Control release formulation containing a hydrophobic material as the sustained release agent
SI1416842T1 (sl)	2001-07-18	2009-06-30	Euro Celtique Sa	Farmacevtske kombinacije oksikodona in naloksona
US20030157168A1 (en)	2001-08-06	2003-08-21	Christopher Breder	Sequestered antagonist formulations
US20030068375A1 (en)	2001-08-06	2003-04-10	Curtis Wright	Pharmaceutical formulation containing gelling agent
IL160222A0 (en)	2001-08-06	2004-07-25	Euro Celtique Sa	Opioid agonist formulations with releasable and sequestered antagonist
US20030044458A1 (en)	2001-08-06	2003-03-06	Curtis Wright	Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030099711A1 (en) *	2001-08-29	2003-05-29	David Meadows	Sustained release preparations
JP4925526B2 (ja) *	2001-09-10	2012-04-25	旭化成ケミカルズ株式会社	薬物の混合方法
AR036797A1 (es)	2001-10-15	2004-10-06	Ferring Bv	Un metodo para preparar una composicion farmaceutica que comprende acido 5-aminosalicilico para utilizar en el tratamiento de colitis ulcerosa y enfermedades de crohn
IL146462A (en) *	2001-11-13	2015-02-26	Lycored Bio Ltd	Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
FR2832632B1 (fr)	2001-11-26	2004-04-23	Mane Fils V	Capsule a solubilisation et liberation du contenu rapides
US20030118647A1 (en) *	2001-12-04	2003-06-26	Pawan Seth	Extended release tablet of metformin
WO2004026235A2 (en) *	2002-09-20	2004-04-01	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
US7927613B2 (en) *	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
WO2004000284A1 (en)	2002-06-21	2003-12-31	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions with improved dissolution
US7790905B2 (en)	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US20090088443A1 (en) *	2002-02-15	2009-04-02	Julius Remenar	Novel crystalline forms of conazoles and methods of making and using the same
CA2477923C (en)	2002-03-01	2021-02-23	University Of South Florida	Multiple-component solid phases containing at least one active pharmaceutical ingredient
HUE032656T2 (en) *	2002-04-05	2017-10-30	Euro Celtique Sa	Pharmaceutical composition containing oxicodone and naloxone
US6958161B2 (en) *	2002-04-12	2005-10-25	F H Faulding & Co Limited	Modified release coated drug preparation
JP2005538105A (ja) *	2002-07-25	2005-12-15	ファルマシア・コーポレーション	水不溶性ポリマーおよび水溶性の小孔形成物質からなる２層により被覆された固体剤形の製造方法
AR040682A1 (es) *	2002-07-25	2005-04-13	Pharmacia Corp	Forma de dosificacion una vez al dia de pramipexol
US20050226926A1 (en)	2002-07-25	2005-10-13	Pfizer Inc	Sustained-release tablet composition of pramipexole
AR040680A1 (es) *	2002-07-25	2005-04-13	Pharmacia Corp	Composicion de tabletas de liberacion sostenida
US20040016276A1 (en) *	2002-07-26	2004-01-29	Wynnyk Nick P.	Controlled release fertilizer having improved mechanical handling durability and method for production thereof
DK1894562T3 (da)	2002-08-15	2011-03-28	Euro Celtique Sa	Farmaceutiske sammensætninger omfattende en opioidantagonist
US20040043064A1 (en) *	2002-08-29	2004-03-04	Iorio Theodore L.	Dosage forms having reduced moisture transmission
CN1703200B (zh)	2002-09-20	2012-02-29	奥尔制药公司	隔离亚单元和相关组合物及方法
ES2206047B1 (es) *	2002-10-22	2005-08-01	Universidad De Granada	Sintesis de un transportador de morfina para formas farmaceuticas liquidas orales de accion controlada.
US20060148877A1 (en) *	2002-11-26	2006-07-06	Transform Pharmaceuticals, Inc.	Pharmaceutical formulations of celcoxib
ATE482695T1 (de)	2002-12-13	2010-10-15	Durect Corp	Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
EP2339328A3 (de)	2002-12-30	2011-07-13	Transform Pharmaceuticals, Inc.	Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
US20040202717A1 (en)	2003-04-08	2004-10-14	Mehta Atul M.	Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en)	2003-04-21	2008-07-31	Euro Celtique Sa	Pharmaceutical products
MXPA05011071A (es) *	2003-04-21	2005-12-12	Euro Celtique Sa	Forma de dosificacion resistente a la alteracion que comprende particulas co-extrusionadas de agente adverso y proceso de fabricacion de las misma.
CA2520197A1 (en) *	2003-04-23	2004-11-04	Ferring B.V.	Sachet for a pharmaceutical composition
GB2402679A (en) *	2003-06-10	2004-12-15	Reckitt Benckiser Nv	Automatic washing machine detergent dispensing device
US7632521B2 (en) *	2003-07-15	2009-12-15	Eurand, Inc.	Controlled release potassium chloride tablets
US20050147663A1 (en) *	2003-07-17	2005-07-07	Mohan Mailatur S.	Method of treatment for improved bioavailability
US20050042277A1 (en) *	2003-07-17	2005-02-24	Irukulla Srinivas	Pharmaceutical compositions having a swellable coating
FR2859729B1 (fr) *	2003-09-12	2006-02-24	Roquette Freres	Dispersions aqueuses d'au moins un polymere biodegradable
PL1663229T3 (pl)	2003-09-25	2010-09-30	Euro Celtique Sa	Farmaceutyczne kombinacje hydrokodonu i naltreksonu
ES2281851T3 (es) *	2003-12-09	2007-10-01	Euro-Celtique S.A.	Forma de dosis co-extruida resistente a la manipulacion conteniendo un agente activo y un agente adverso y proceso para preparar el mismo.
US8883204B2 (en) *	2003-12-09	2014-11-11	Purdue Pharma L.P.	Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
US20050176680A1 (en)	2003-12-11	2005-08-11	Sepracor, Inc.	Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
EP1547601A1 (de)	2003-12-23	2005-06-29	Ferring B.V.	Beschichtungsverfahren
KR100963914B1 (ko)	2004-03-30	2010-06-17	유로-셀띠끄 소시에떼 아노님	흡착제 및 억제제를 포함하는 내변조성 제형
TWI365880B (en) *	2004-03-30	2012-06-11	Euro Celtique Sa	Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
EP1604667A1 (de)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioide zur Behandlung des Restless Leg Syndroms
EP1604666A1 (de)	2004-06-08	2005-12-14	Euro-Celtique S.A.	Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
PT1765292T (pt)	2004-06-12	2017-12-29	Collegium Pharmaceutical Inc	Formulações de fármacos dissuasoras de abuso
EA200700388A1 (ru) *	2004-08-13	2007-08-31	Бёрингер Ингельхайм Интернациональ Гмбх	Композиция пеллеты пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ её изготовления и её применение
HRP20100682T4 (hr) *	2004-08-13	2014-08-01	Boehringer Ingelheim International Gmbh	Formulacija tablete produljenog oslobađanja koja sadrži pramipeksol ili njegovu farmaceutski prihvatljivu sol, postupak njezine priprave i uporaba
CN101010072A (zh) *	2004-09-01	2007-08-01	欧洲凯尔特公司	具有与剂量成比例的稳态Cave和AUC并且小于与剂量成比例的单剂量CMAX的阿片类物质剂量形式
US20060093629A1 (en) *	2004-10-29	2006-05-04	Buehler Gail K	Dye-free pharmaceutical suspensions and related methods
GB0427455D0 (en) *	2004-12-15	2005-01-19	Jagotec Ag	Dosage forms
EA014249B1 (ru) *	2005-01-27	2010-10-29	Алембик Лимитед	Формуляция леветирацетама длительного высвобождения
GEP20105052B (en) *	2005-01-28	2010-07-26	Euro Celtique Sa	Alcohol resistant dosage forms
EP1702558A1 (de)	2005-02-28	2006-09-20	Euro-Celtique S.A.	Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1695700A1 (de) *	2005-02-28	2006-08-30	Euro-Celtique S.A.	Darreichungsform enthaltend Oxycodon und Naloxon
EP1754471A1 (de)	2005-08-18	2007-02-21	ORAMON-Arzneimittel GmbH & Co. KG	Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
EP1813276A1 (de) *	2006-01-27	2007-08-01	Euro-Celtique S.A.	Manipulationssichere Dosierformen
SI3095447T1 (sl)	2006-02-03	2022-02-28	Opko Renal, Llc	Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
WO2007092718A2 (en) *	2006-02-07	2007-08-16	Fmc Corporation	Coating process to produce controlled release coatings
US20090098202A1 (en) *	2006-02-10	2009-04-16	Boehringer Ingelheim International Gmbh	Extended Release Formulation
CA2641665A1 (en) *	2006-02-10	2007-08-16	Boehringer Ingelheim International Gmbh	Modified release formulation
US20070190141A1 (en) *	2006-02-16	2007-08-16	Aaron Dely	Extended release opiate composition
FR2897267A1 (fr) *	2006-02-16	2007-08-17	Flamel Technologies Sa	Formes pharmaceutiques multimicroparticulaires pour administration per os
US20080069891A1 (en) *	2006-09-15	2008-03-20	Cima Labs, Inc.	Abuse resistant drug formulation
SI2719378T1 (sl)	2006-06-19	2016-11-30	Alpharma Pharmaceuticals Llc	Farmacevtski sestavki
HUE037309T2 (hu)	2006-06-21	2018-08-28	Opko Ireland Global Holdings Ltd	Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
SA07280459B1 (ar)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en)	2006-09-15	2013-05-21	Cima Labs Inc.	Abuse resistant drug formulation
GB0624880D0 (en) *	2006-12-14	2007-01-24	Johnson Matthey Plc	Improved method for making analgesics
EP2124564A1 (de) *	2007-01-10	2009-12-02	Bayer CropScience AG	Insektizide düngemittelmischungen
US7879747B2 (en)	2007-03-30	2011-02-01	Kimberly-Clark Worldwide, Inc.	Elastic laminates having fragrance releasing properties and methods of making the same
PL2148661T3 (pl)	2007-04-25	2013-07-31	Cytochroma Inc	Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
DK2148684T3 (da)	2007-04-25	2013-04-22	Cytochroma Inc	Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens
PT3335712T (pt)	2007-04-25	2025-10-23	Opko Renal Llc	Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
US8007707B1 (en)	2007-05-15	2011-08-30	Fresh Products, Inc.	Method of manufacture air freshening article
EP2200613B1 (de)	2007-09-21	2018-09-05	The Johns Hopkins University	Phenazin-derivate und ihre verwendungen
PL2057984T3 (pl) *	2007-11-09	2010-05-31	Acino Pharma Ag	Tabletki z hydromorfonem o przedłużonym uwalnianiu
JP2011506319A (ja)	2007-12-06	2011-03-03	デュレクトコーポレーション	疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
US8623418B2 (en)	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
US9226907B2 (en)	2008-02-01	2016-01-05	Abbvie Inc.	Extended release hydrocodone acetaminophen and related methods and uses thereof
US8404260B2 (en)	2008-04-02	2013-03-26	Bayer Cropscience Lp	Synergistic pesticide compositions
CN102046812A (zh)	2008-04-02	2011-05-04	赛特克罗公司	用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
DE102008021473A1 (de) *	2008-04-29	2009-11-12	Heraeus Kulzer Gmbh	Mit Antiplaque-Wirkstoff(en) ausgestattete Dentalmaterialien
US7883638B2 (en)	2008-05-27	2011-02-08	Dober Chemical Corporation	Controlled release cooling additive compositions
US20100003322A1 (en) *	2008-07-03	2010-01-07	Lai Felix S	Enteric coated hydrophobic matrix formulation
US20100260844A1 (en)	2008-11-03	2010-10-14	Scicinski Jan J	Oral pharmaceutical dosage forms
CN102245171A (zh) *	2008-11-10	2011-11-16	株式会社爱茉莉太平洋	缓释微粒及其制备方法
EP2448406B1 (de)	2009-02-26	2016-04-20	Relmada Therapeutics, Inc.	Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
SG174286A1 (en)	2009-03-10	2011-10-28	Euro Celtique Sa	Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en)	2009-12-10	2020-06-02	Collegium Pharmaceutical, Inc.	Tamper-resistant pharmaceutical compositions of opioids and other drugs
PT2552484T (pt)	2010-03-29	2020-04-03	Opko Ireland Global Holdings Ltd	Métodos e composições para redução dos níveis de parafróides
US20120090366A1 (en) *	2010-04-16	2012-04-19	Taylor Pursell	Controlled release fertilizer with biopolymer coating and process for making same
CA2798702A1 (en)	2010-05-11	2011-11-17	Cima Labs Inc.	Alcoholresistant metoprolol-containing extended-release oral dosage forms
EP3485878A1 (de)	2010-09-01	2019-05-22	Arena Pharmaceuticals, Inc.	Darreichungsformen von 5-ht2c-agonisten, die nützlich für gewichtskontrolle sind
HUE034955T2 (en)	2010-12-22	2018-03-28	Purdue Pharma Lp	Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en)	2010-12-23	2022-10-24	Purdue Pharma Lp	Tamper resistant solid oral dosage forms
US20120328697A1 (en) *	2011-06-01	2012-12-27	Fmc Corporation	Controlled Release Solid Dose Forms
US9243394B2 (en)	2011-09-20	2016-01-26	Fresh Products, Inc.	Replaceable restroom urinal assemblies, including urinal screens
JP6368242B2 (ja) *	2011-10-06	2018-08-01	ノバルティスアーゲー	４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
WO2013126552A1 (en)	2012-02-21	2013-08-29	Auburn University	Buprenorphine nanoparticle composition and methods thereof
KR102196741B1 (ko)	2012-04-17	2020-12-30	퍼듀 퍼머 엘피	오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법
BR112015000320B1 (pt)	2012-07-12	2023-03-07	SpecGx LLC	Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
TWI588147B (zh)	2012-07-16	2017-06-21	羅德科技公司	改良之類鴉片合成方法
CA2879270C (en)	2012-07-16	2017-09-05	Rhodes Technologies	Process for improved opioid synthesis
MX2015010041A (es)	2013-02-05	2015-10-30	Purdue Pharma Lp	Formulacion farmaceuticas resistentes a la alteracion.
AU2014233453A1 (en)	2013-03-15	2015-10-01	Durect Corporation	Compositions with a rheological modifier to reduce dissolution variability
KR101847947B1 (ko)	2013-03-15	2018-05-28	옵코 아이피 홀딩스 Ⅱ 인코포레이티드	안정화되고 변형된 비타민 ｄ 방출 제형
US10751287B2 (en)	2013-03-15	2020-08-25	Purdue Pharma L.P.	Tamper resistant pharmaceutical formulations
JP2016525138A (ja)	2013-07-23	2016-08-22	ユーロ−セルティークエス．エイ．	疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
WO2015015146A1 (en)	2013-08-02	2015-02-05	Johnson Matthey Public Limited Company	Process for the preparation of oxymorphone
WO2015065547A1 (en)	2013-10-31	2015-05-07	Cima Labs Inc.	Immediate release abuse-deterrent granulated dosage forms
US9938285B2 (en)	2014-01-15	2018-04-10	Rhodes Technologies	Process for improved oxymorphone synthesis
US9932348B2 (en)	2014-01-15	2018-04-03	Rhodes Technologies	Process for improved oxycodone synthesis
US9062063B1 (en)	2014-03-21	2015-06-23	Johnson Matthey Public Limited Company	Forms of oxymorphone hydrochloride
EP2937096B1 (de)	2014-04-23	2019-08-21	Julius-Maximilians-Universität Würzburg	Aus RS1 abgeleitete Peptide, die Glukoseabsorption nach einer glukosereichen Mahlzeit herunterregulieren und die Insulinsensitivität steigern
US9962336B2 (en)	2014-05-01	2018-05-08	Sun Pharmaceutical Industries Limited	Extended release suspension compositions
US20180104197A9 (en) *	2014-05-01	2018-04-19	Sun Pharmaceutical Industries Limited	Extended release liquid compositions of metformin
US10258583B2 (en)	2014-05-01	2019-04-16	Sun Pharmaceutical Industries Limited	Extended release liquid compositions of guanfacine
EP3137060B2 (de)	2014-05-01	2023-12-20	Sun Pharmaceutical Industries Ltd	Suspensionszusammensetzungen mit verlängerter freisetzung
AU2015294912A1 (en)	2014-07-30	2017-02-16	Sun Pharmaceutical Industries Limited	Dual-chamber pack
CA3193201A1 (en)	2014-05-06	2015-11-12	Anthony G. Visco	Methods of treating or preventing preterm labor
US10220047B2 (en)	2014-08-07	2019-03-05	Opko Ireland Global Holdings, Ltd.	Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US20170182070A1 (en)	2014-10-08	2017-06-29	Mayne Pharma International Pty Ltd.	Controlled Release Doxycycline
US9849124B2 (en)	2014-10-17	2017-12-26	Purdue Pharma L.P.	Systems and methods for treating an opioid-induced adverse pharmacodynamic response
USD778411S1 (en)	2014-11-05	2017-02-07	Fresh Products, Inc.	Urinal screen
DE202015102279U1 (de)	2014-11-05	2015-08-14	Fresh Products, Inc.	Urinalsieb
USD778412S1 (en)	2014-11-10	2017-02-07	Fresh Products, Inc.	Urinal screen
US9918979B2 (en)	2015-01-29	2018-03-20	Johnson Matthey Public Limited Company	Process of preparing low ABUK oxymorphone hydrochloride
HK1245095A1 (zh)	2015-05-20	2018-08-24	Novartis Ag	依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
ES2925951T3 (es)	2015-07-22	2022-10-20	John Hsu	Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
MY198547A (en)	2016-03-28	2023-09-04	Opko Ireland Global Holdings Ltd	Methods of vitamin d treatment
US10238803B2 (en)	2016-05-02	2019-03-26	Sun Pharmaceutical Industries Limited	Drug delivery device for pharmaceutical compositions
US10369078B2 (en)	2016-05-02	2019-08-06	Sun Pharmaceutical Industries Limited	Dual-chamber pack for pharmaceutical compositions
US9737530B1 (en)	2016-06-23	2017-08-22	Collegium Pharmaceutical, Inc.	Process of making stable abuse-deterrent oral formulations
US12274794B2 (en)	2016-07-06	2025-04-15	Orient Pharma Co., Ltd.	Oral dosage form with drug composition, barrier layer and drug layer
CN110114070A (zh)	2016-11-23	2019-08-09	诺华公司	使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
JP2020526500A (ja)	2017-06-30	2020-08-31	パーデュー、ファーマ、リミテッド、パートナーシップ	治療方法及びその剤形
US12053464B2 (en) *	2017-10-20	2024-08-06	Purdue Pharma L.P.	Pharmaceutical dosage forms
AU2018390826B2 (en)	2017-12-20	2024-09-12	Purdue Pharma L.P.	Abuse deterrent morphine sulfate dosage forms
AU2018388576A1 (en)	2017-12-20	2020-07-23	Fresh Products, Inc.	Urinal screens
US10596165B2 (en)	2018-02-12	2020-03-24	resTORbio, Inc.	Combination therapies
EP3594194A1 (de)	2018-07-12	2020-01-15	Casale Sa	Harnstoffgranulationsverfahren
CN108958335B (zh) *	2018-07-27	2021-08-24	中国兵器工业第五九研究所	一种气候模块化数控贮存试验系统
USD925009S1 (en)	2018-10-25	2021-07-13	Fresh Products, Inc.	Urinal screen
US12589083B2 (en)	2019-05-07	2026-03-31	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
US11324707B2 (en)	2019-05-07	2022-05-10	Clexio Biosciences Ltd.	Abuse-deterrent dosage forms containing esketamine
US20210315283A1 (en) *	2020-04-13	2021-10-14	Aki, Inc.	Disposable diffusing collar stay
WO2022167359A1 (en)	2021-02-02	2022-08-11	DuPont Nutrition USA, Inc.	An aqueous gel composition comprising an ethylcellulose
USD1078945S1 (en)	2022-07-13	2025-06-10	Fresh Products, Inc.	Urinal screen
CN115844854B (zh) *	2022-10-26	2025-02-18	沈阳药科大学	一种微囊型自悬浮茶碱缓释颗粒及其制备方法
CN119139256B (zh) *	2024-09-14	2025-05-27	安徽瑞旗药业有限公司	一种富马酸依美斯汀制剂及其制备方法
CN121058684A (zh) *	2025-08-27	2025-12-05	湖南农业大学	一种定时释放农药及其制备方法和应用

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3567650A (en) *	1969-02-14	1971-03-02	Ncr Co	Method of making microscopic capsules
US3870790A (en) *	1970-01-22	1975-03-11	Forest Laboratories	Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
GB1561204A (en) *	1977-06-01	1980-02-13	Ici Ltd	Sustained release pharmaceutical composition
JPS5535031A (en) *	1978-09-04	1980-03-11	Shin Etsu Chem Co Ltd	Enteric coating composition
JPS57120518A (en) *	1981-01-19	1982-07-27	Tanabe Seiyaku Co Ltd	Preparation of microcapsule
US4377568A (en) *	1981-08-12	1983-03-22	Merck Sharp & Dohme (I.A.) Corp.	Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS60166608A (ja) *	1984-02-08	1985-08-29	Japan Atom Energy Res Inst	サンドイツチ構造をもつ徐放性複合体およびその製造方法
US4795327A (en) *	1984-03-26	1989-01-03	Forest Laboratories, Inc.	Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) *	1984-03-26	1989-07-18	Forest Laboratories, Inc.	Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4600645A (en) *	1985-01-31	1986-07-15	Warner-Lambert Company	Process for treating dosage forms
GB2170104A (en) *	1985-01-30	1986-07-30	Warner Lambert Co	Coated pharmaceutical dosage forms
US5186937A (en) *	1985-06-07	1993-02-16	A.E.C. Societe De Chimie Organique Et Biologique	Composition for feeding ruminants
GB8521494D0 (en) *	1985-08-29	1985-10-02	Zyma Sa	Controlled release tablet
IT1214629B (it) *	1985-08-29	1990-01-18	Formenti Farmaceutici Spa	Procedimento di microincapsulazione di un medicamento,medicamento cosi'preparato,e composizioni farmaceutiche che lo comprendono
US4837004A (en) *	1985-10-18	1989-06-06	Eastman Kodak Company	Rumen-stable pellets
IT1204294B (it) *	1986-03-11	1989-03-01	Gentili Ist Spa	Metodo di fabbricazione di granulari atti a produzione di compresse rivestite,per uso orale,a rilascio controllato
US4756911A (en) *	1986-04-16	1988-07-12	E. R. Squibb & Sons, Inc.	Controlled release formulation
GB2189699A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
US4810501A (en) *	1986-06-17	1989-03-07	Warner-Lambert Company	Sustained release pharmaceutical preparations
GB8626098D0 (en) *	1986-10-31	1986-12-03	Euro Celtique Sa	Controlled release hydromorphone composition
GB8707416D0 (en) *	1987-03-27	1987-04-29	Wellcome Found	Pharmaceutical formulations
JP2668880B2 (ja) *	1987-06-23	1997-10-27	日本油脂株式会社	被覆アミノ酸類の製造方法
US5068110A (en) *	1987-09-29	1991-11-26	Warner-Lambert Company	Stabilization of enteric coated dosage form
US5219621A (en) *	1987-10-16	1993-06-15	Elan Corporation, Plc	Methods of treatment with diltiazem formulations
FR2624732B1 (fr) *	1987-12-21	1991-02-15	Synthelabo	Formulation pharmaceutique a liberation prolongee
US4837033A (en) *	1987-12-22	1989-06-06	Shin-Etsu Chemical Co., Ltd.	Method for the preparation of a coated solid medicament
US5064650A (en) *	1988-04-19	1991-11-12	Southwest Research Institute	Controlled-release salt sensitive capsule for oral use and adhesive system
US5169642A (en) *	1988-06-24	1992-12-08	Abbott Laboratories	Sustained-release drug dosage units
US5009897A (en) *	1988-06-24	1991-04-23	Abbott Laboratories	Pharmaceutical granules and tablets made therefrom
US4983730A (en) *	1988-09-02	1991-01-08	Hoechst Celanese Corporation	Water soluble cellulose acetate composition having improved processability and tensile properties
IT1230576B (it) *	1988-10-20	1991-10-28	Angeli Inst Spa	Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5085866A (en) *	1988-12-02	1992-02-04	Southern Research Institute	Method of producing zero-order controlled-released devices
US5202128A (en) *	1989-01-06	1993-04-13	F. H. Faulding & Co. Limited	Sustained release pharmaceutical composition
US5133974A (en) *	1989-05-05	1992-07-28	Kv Pharmaceutical Company	Extended release pharmaceutical formulations
US5084278A (en) *	1989-06-02	1992-01-28	Nortec Development Associates, Inc.	Taste-masked pharmaceutical compositions
US5047258A (en) *	1989-07-14	1991-09-10	Sterling Drug Inc.	Aqueous spray-coating process
JPH0361474A (ja) *	1989-07-31	1991-03-18	Izumi Enterp:Kk	清酒又はブドウ酒を、風味を損なわずに希釈して、低濃度のアルコール飲料とするために用いる割り水
PH27186A (en) *	1989-09-07	1993-04-16	Ciba Geigy Ag	Double-coated granules of disodium pamidronate
IL96311A (en) *	1989-12-01	1995-05-26	Abbott Lab	Medications with delayed release
US5077053A (en) *	1990-02-12	1991-12-31	Warner-Lambert Company	Zein as a moisture barrier for sugarless edible compositions and method for preparing same
US5158777A (en) *	1990-02-16	1992-10-27	E. R. Squibb & Sons, Inc.	Captopril formulation providing increased duration of activity
CA2036907C (en) *	1990-02-28	1996-10-22	Yuzo Miura	3-(substituted phenyl) pyrazole derivatives, a process for producing the same, herbicidal composition containing the same and method of controlling weeds using said composition
US5178866A (en) *	1990-03-23	1993-01-12	Alza Corporation	Dosage form for delivering drug to the intestine
US5091175A (en) *	1990-05-14	1992-02-25	Erbamont Inc.	Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
US5042842A (en) *	1990-06-26	1991-08-27	Avery International Corporation	High security label
JP2558396B2 (ja) *	1990-06-28	1996-11-27	田辺製薬株式会社	放出制御型製剤
US5213811A (en) *	1991-09-13	1993-05-25	Sterling Drug Inc.	Oral sustained-release drug compositions
US5286493A (en) *	1992-01-27	1994-02-15	Euroceltique, S.A.	Stabilized controlled release formulations having acrylic polymer coating
US5273760A (en) *	1991-12-24	1993-12-28	Euroceltigue, S.A.	Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5472712A (en) *	1991-12-24	1995-12-05	Euroceltique, S.A.	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5160742A (en) *	1991-12-31	1992-11-03	Abbott Laboratories	System for delivering an active substance for sustained release
SE9301057L (sv) *	1993-03-30	1994-10-01	Pharmacia Ab	Beredning med kontrollerad frisättning

1993
- 1993-06-23 US US08/081,618 patent/US5472712A/en not_active Expired - Lifetime
1994
- 1994-06-14 EP EP04025135A patent/EP1504757A3/de not_active Withdrawn
- 1994-06-14 DE DE69434515T patent/DE69434515T2/de not_active Expired - Lifetime
- 1994-06-14 AT AT94109115T patent/ATE221375T1/de not_active IP Right Cessation
- 1994-06-14 DK DK04018826T patent/DK1477162T3/da active
- 1994-06-14 ES ES04018826T patent/ES2315599T3/es not_active Expired - Lifetime
- 1994-06-14 SI SI9430479T patent/SI1419766T1/sl unknown
- 1994-06-14 DE DE69431089T patent/DE69431089T2/de not_active Revoked
- 1994-06-14 DE DE69435145T patent/DE69435145D1/de not_active Expired - Lifetime
- 1994-06-14 PT PT04018826T patent/PT1477162E/pt unknown
- 1994-06-14 EP EP01130255A patent/EP1203581A3/de not_active Withdrawn
- 1994-06-14 EP EP04003055A patent/EP1419766B1/de not_active Expired - Lifetime
- 1994-06-14 EP EP94109115A patent/EP0630646B1/de not_active Revoked
- 1994-06-14 SI SI9430489T patent/SI1477162T1/sl unknown
- 1994-06-14 EP EP04025137A patent/EP1504758A3/de not_active Withdrawn
- 1994-06-14 EP EP04018825A patent/EP1475085A1/de not_active Ceased
- 1994-06-14 AT AT04018826T patent/ATE409024T1/de active
- 1994-06-14 EP EP04025136A patent/EP1502591A3/de not_active Ceased
- 1994-06-14 ES ES04003055T patent/ES2252711T3/es not_active Expired - Lifetime
- 1994-06-14 PT PT94109115T patent/PT630646E/pt unknown
- 1994-06-14 ES ES94109115T patent/ES2180552T3/es not_active Expired - Lifetime
- 1994-06-14 DK DK94109115T patent/DK0630646T3/da active
- 1994-06-14 EP EP04018826A patent/EP1477162B1/de not_active Revoked
- 1994-06-14 DK DK04003055T patent/DK1419766T3/da active
- 1994-06-14 EP EP08162715A patent/EP2018852A1/de not_active Ceased
- 1994-06-14 AT AT04003055T patent/ATE306909T1/de active
- 1994-06-15 CA CA002125904A patent/CA2125904C/en not_active Expired - Lifetime
- 1994-06-20 AU AU64846/94A patent/AU680491B2/en not_active Expired
- 1994-06-22 NO NO19942382A patent/NO314566B1/no not_active IP Right Cessation
- 1994-06-22 FI FI943022A patent/FI121620B/fi not_active IP Right Cessation
- 1994-06-23 JP JP14201294A patent/JP4505059B2/ja not_active Expired - Lifetime
1997
- 1997-10-31 AU AU43687/97A patent/AU704524B2/en not_active Expired
2002
- 2002-11-07 HK HK02108097.3A patent/HK1048432A1/en unknown
2006
- 2006-04-11 JP JP2006109017A patent/JP4703471B2/ja not_active Expired - Fee Related
- 2006-04-11 JP JP2006108991A patent/JP4703470B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69435145D1 (de)	2008-11-06
EP2018852A1 (de)	2009-01-28
JP4505059B2 (ja)	2010-07-14
JP4703470B2 (ja)	2011-06-15
FI943022A0 (fi)	1994-06-22
EP1502591A3 (de)	2006-02-08
US5472712A (en)	1995-12-05
EP1475085A1 (de)	2004-11-10
PT1477162E (pt)	2008-12-17
AU4368797A (en)	1998-01-22
AU6484694A (en)	1995-01-19
EP1502591A2 (de)	2005-02-02
JP4703471B2 (ja)	2011-06-15
EP0630646A1 (de)	1994-12-28
NO942382D0 (de)	1994-06-22
PT630646E (pt)	2002-12-31
EP1504758A3 (de)	2006-04-12
EP1477162A1 (de)	2004-11-17
AU704524B2 (en)	1999-04-29
NO942382L (no)	1994-12-27
CA2125904A1 (en)	1994-12-24
ES2315599T3 (es)	2009-04-01
FI943022L (fi)	1994-12-24
HK1048432A1 (en)	2003-04-04
JP2006188540A (ja)	2006-07-20
DK1419766T3 (da)	2006-03-06
CA2125904C (en)	2000-08-08
EP1419766A1 (de)	2004-05-19
EP1203581A2 (de)	2002-05-08
DE69431089T2 (de)	2003-03-27
EP1477162B1 (de)	2008-09-24
EP1203581A3 (de)	2002-12-11
DE69434515T2 (de)	2006-07-06
SI1419766T1 (sl)	2006-04-30
ES2252711T3 (es)	2006-05-16
ES2180552T3 (es)	2003-02-16
FI121620B (fi)	2011-02-15
ATE409024T1 (de)	2008-10-15
JPH07138189A (ja)	1995-05-30
EP1504758A2 (de)	2005-02-09
JP2006188539A (ja)	2006-07-20
DE69431089D1 (de)	2002-09-05
EP1504757A3 (de)	2006-04-12
DK1477162T3 (da)	2009-01-12
EP1504757A2 (de)	2005-02-09
DK0630646T3 (da)	2002-11-25
ATE221375T1 (de)	2002-08-15
EP0630646B1 (de)	2002-07-31
ATE306909T1 (de)	2005-11-15
EP1419766B1 (de)	2005-10-19
SI1477162T1 (sl)	2009-02-28
AU680491B2 (en)	1997-07-31
DE69434515D1 (de)	2006-03-02

Legal Events

Date	Code	Title	Description
2014-06-30	MK1K	Patent expired

Publication	Publication Date	Title
NO314566B1 (no)	2003-04-14	Doseringsform med regulert frigivelse belagt med vandige dispersjoner av etylcellulose, samt fremgangsmåte og anvendelse
AU686168B2 (en)	1998-02-05	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US7070806B2 (en)	2006-07-04	Controlled release formulations coated with aqueous dispersions of acrylic polymers
NO314711B1 (no)	2003-05-12	Tabletter med forlenget frigivelse for oral administrering og fremgangsmåter for fremstilling derav
US20020012700A1 (en)	2002-01-31	Combination dosage form comprising cetirizine and pseudoephedrine
NO312577B1 (no)	2002-06-03	Fremgangsmåte for fremstilling av en stabilisert formulering med regulert frigivelse omfattende et substrat belagt med envandig dispersjon av etylcellulose
JP2005516020A (ja)	2005-06-02	ゼロ次持続放出剤形およびその製造方法
NO309360B1 (no)	2001-01-22	Stabilisert, fast doseringsform med kontrollert frigivelse av en dose av et terapeutisk aktivt middel og fremgangsmåte for fremstilling av denne
JPH08175977A (ja)	1996-07-09	アクリル系ポリマーの水性分散液で被覆した放出制御型製剤及びその製法
HK1073602A (en)	2005-10-14	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
HK1073251A (en)	2005-09-30	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
HK1072189A (en)	2005-08-19	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
HK1075398A (en)	2005-12-16	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
JP5146859B2 (ja)	2013-02-20	アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
HK1072190A1 (en)	2005-08-19	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
HK1072190B (en)	2009-06-19	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
HK1129834A (en)	2009-12-11	Controlled-release formulations coated with aqueous dispersions of ethylcellulose
JP2008024708A (ja)	2008-02-07	アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法